The New England Journal of Medicine recently published an article regarding phase three of a clinical trial testing osimertinib, an oral first-line treatment for patients with previously untreated epidermal growth factor receptor (EGFR) mutation-positive, advanced non-small-cell lung cancer (NSCLC). Oncogenic EGFR mutations are correlated with NSCLCs. EGFR, a transmembrane tyrosine kinase, regulates cellular proliferation and […]

Read More →